239 related articles for article (PubMed ID: 35929392)
1. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?].
Villain N
Geriatr Psychol Neuropsychiatr Vieil; 2022 Jun; 20(2):256-260. PubMed ID: 35929392
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
Villain N
Rev Neurol (Paris); 2022 May; 178(5):437-440. PubMed ID: 35489824
[TBL] [Abstract][Full Text] [Related]
3. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
Parums DV
Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
[TBL] [Abstract][Full Text] [Related]
5. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):999-1010. PubMed ID: 36336488
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease: Recent treatment strategies.
Vaz M; Silvestre S
Eur J Pharmacol; 2020 Nov; 887():173554. PubMed ID: 32941929
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
9. Passive immunotherapy for Alzheimer's disease.
Guo X; Yan L; Zhang D; Zhao Y
Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A; Blanc F; Collongues N
Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
[TBL] [Abstract][Full Text] [Related]
11. [Causal treatment of Alzheimer's disease: amyloid antibodies].
Pawlowski M; Warnecke T
Inn Med (Heidelb); 2022 Sep; 63(9):1000-1008. PubMed ID: 35290498
[TBL] [Abstract][Full Text] [Related]
12. Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics.
Osaka H; Nishida K; Kanazawa T
PCN Rep; 2024 Mar; 3(1):e185. PubMed ID: 38868475
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapies in Alzheimer's disease: state of the art and potential use in the elderly].
Delrieu J; Ousset PJ
Geriatr Psychol Neuropsychiatr Vieil; 2023 Jun; 21(2):233-240. PubMed ID: 37519082
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
15. Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
[TBL] [Abstract][Full Text] [Related]
16. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro S; Valeri A; Mazzon E
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
[TBL] [Abstract][Full Text] [Related]
17. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
18. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
Zhang J
Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
[TBL] [Abstract][Full Text] [Related]
19. Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.
Hao W; Lenhart S; Petrella JR
PLoS Comput Biol; 2022 Sep; 18(9):e1010481. PubMed ID: 36054214
[TBL] [Abstract][Full Text] [Related]
20. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
Park KW
Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
